Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Tenofovir Disoproxil→

Tenofovir Disoproxil Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
201341-05-1
Molecular formula
C19H30N5O10P
Molecular weight
519.4 g/mol
Drug class
Acyclic nucleotide phosphonate prodrugantiretroviral reverse-transcriptase inhibitor precursor
Mechanism of action
Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents
  • Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring

Sources: US DailyMed — Tenofovir disoproxil fumarate · EMA — Viread · NIH HIV drug information — Tenofovir disoproxil fumarate

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Tenofovir Disoproxil Environmental Risk Assessment (ERA) (the Tenofovir Disoproxil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.